AstraZeneca’s COPD Triple Combo Drug Succeeds in ETHOS Phase III, Setting Up GSK Showdown
The triple-combination treatment significantly reduced COPD exacerbations compared to older dual therapies in the Phase III ETHOS study, providing a boost to AstraZeneca as it closes in on approvals in the US and Europe.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
GlaxoSmithKline is streets ahead in the three-in-one COPD market, having received approval last year in the USA and Europe for Trelegy Ellipta, but AstraZeneca's PT010 may provide competition in the future having met six out of seven lung function primary endpoints in a Phase III trial.
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.